CN108289966A - 用于减少转移的方法和组合物 - Google Patents

用于减少转移的方法和组合物 Download PDF

Info

Publication number
CN108289966A
CN108289966A CN201680068791.9A CN201680068791A CN108289966A CN 108289966 A CN108289966 A CN 108289966A CN 201680068791 A CN201680068791 A CN 201680068791A CN 108289966 A CN108289966 A CN 108289966A
Authority
CN
China
Prior art keywords
seq
polypeptide
trap
region
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680068791.9A
Other languages
English (en)
Chinese (zh)
Inventor
L.黄
T.古德温
R.刘
L.苗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of CN108289966A publication Critical patent/CN108289966A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680068791.9A 2015-09-24 2016-09-15 用于减少转移的方法和组合物 Pending CN108289966A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562232169P 2015-09-24 2015-09-24
US62/232169 2015-09-24
PCT/US2016/051966 WO2017053170A1 (en) 2015-09-24 2016-09-15 Methods and compositions for reducing metastases

Publications (1)

Publication Number Publication Date
CN108289966A true CN108289966A (zh) 2018-07-17

Family

ID=58386932

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680068791.9A Pending CN108289966A (zh) 2015-09-24 2016-09-15 用于减少转移的方法和组合物

Country Status (10)

Country Link
US (2) US11219694B2 (enExample)
EP (1) EP3352800B1 (enExample)
JP (2) JP6933379B2 (enExample)
KR (1) KR20180063885A (enExample)
CN (1) CN108289966A (enExample)
AU (1) AU2016328279A1 (enExample)
CA (1) CA2999756A1 (enExample)
ES (1) ES2907486T3 (enExample)
IL (1) IL258292A (enExample)
WO (1) WO2017053170A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109923123A (zh) * 2016-10-14 2019-06-21 爱默蕾大学 具有结合或阻断pd-l1的分子的纳米颗粒及其在治疗癌症中的用途
WO2021043337A1 (zh) * 2019-09-06 2021-03-11 中国药科大学 一种多肽及其应用
CN113912695A (zh) * 2019-07-24 2022-01-11 暨南大学 靶向cd133的结合蛋白及应用
CN115068496A (zh) * 2022-06-29 2022-09-20 四川大学 Dna四面体框架核酸和香蒲新苷的复合物及其制备治疗急性肾损伤的药物的用途
CN118256447A (zh) * 2024-04-26 2024-06-28 中国医学科学院北京协和医院 一种高转移能力的胰腺癌类器官及其构建方法和应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180063885A (ko) 2015-09-24 2018-06-12 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 전이 감소를 위한 방법 및 조성물
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CA3033105A1 (en) * 2016-08-11 2018-02-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds
KR102171766B1 (ko) * 2018-02-02 2020-10-29 주식회사 뉴라클제네틱스 Pd-l1 결합력이 증대된 pd-1 변이체
EP4243852A4 (en) * 2020-11-13 2024-12-11 Ludwig Institute for Cancer Research Ltd PD-1 DECOY VARIANTS FOR IMMUNOTHERAPY
JP2024546654A (ja) * 2021-12-10 2024-12-26 ジョージアミューン・インコーポレイテッド ポリペプチドモジュレーター
WO2024182318A2 (en) * 2023-02-28 2024-09-06 Kodiak Sciences Inc. Antibodies to htra1 and conjugates thereof

Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083750A2 (en) * 2000-04-28 2001-11-08 The Johns Hopkins University Dendritic cell co-stimulator molecules
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
US20050009149A1 (en) * 2002-10-11 2005-01-13 West James W. Production of homotrimeric fusion proteins
US20060110383A1 (en) * 2002-07-03 2006-05-25 Tasuku Honjo Immunopotentiative composition
WO2007024715A2 (en) * 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
CN101124328A (zh) * 2004-12-15 2008-02-13 北卡罗来纳查佩尔山大学 嵌合载体
CN102250254A (zh) * 2010-05-19 2011-11-23 江苏先声药物研究有限公司 肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
CN102282168A (zh) * 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
WO2013071068A2 (en) * 2011-11-09 2013-05-16 Bristol-Myers Squibb Company Treatment of hematologic malignancies with an anti-cxcr4 antibody
US8512701B2 (en) * 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
US20140086835A1 (en) * 2011-05-23 2014-03-27 The University Of North Carolina At Chapel Hill Methods and Compositions for Heptameric Targeting Ligands
CN103857699A (zh) * 2011-05-24 2014-06-11 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
WO2014121085A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Pd-l1 and pd-l2-based fusion proteins and uses thereof
CN104023711A (zh) * 2011-10-14 2014-09-03 Stc.Unm公司 用于靶向递送(包括负载物的透皮递送)的多孔纳米颗粒支撑的脂质双层(原始细胞)及其方法
CN104066449A (zh) * 2012-01-18 2014-09-24 霍夫曼-拉罗奇有限公司 抗lrp5抗体及使用方法
WO2015019284A2 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
JP2015057442A (ja) * 2007-07-10 2015-03-26 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ Ｔｎｆスーパーファミリーコレクチン融合タンパク質
US20150203579A1 (en) * 2014-01-23 2015-07-23 Regeneron Pharmaceuticals, Inc. Human Antibodies to PD-1
CN105085677A (zh) * 2014-05-05 2015-11-25 中国科学院上海药物研究所 抗vegfr2人源纳米抗体ntv1及其制备方法和用途
CN105658237A (zh) * 2013-10-21 2016-06-08 基因泰克公司 抗Ly6E抗体及使用方法
WO2017053170A1 (en) * 2015-09-24 2017-03-30 The University Of North Carolina At Chapel Hill Methods and compositions for reducing metastases
US20170218091A1 (en) * 2014-07-03 2017-08-03 Abbvie Inc. Monovalent binding proteins
CN107108707A (zh) * 2014-08-08 2017-08-29 小利兰斯坦福大学理事会 高亲和力pd‑1药剂以及使用方法
CN108079301A (zh) * 2016-11-23 2018-05-29 四川大学 减少cxcl13蛋白活性或表达量的活性物质在制备治疗恶性肿瘤转移药物中的用途
WO2018160572A1 (en) * 2017-02-28 2018-09-07 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising gitr-binding agents
CN110357960A (zh) * 2018-04-10 2019-10-22 广州爱思迈生物医药科技有限公司 抗体及抗体改造方法
CN112543643A (zh) * 2018-03-05 2021-03-23 肿瘤免疫股份有限公司 使用可溶性cd24用于治疗获得性免疫缺陷综合征（hiv/aids）的方法
CN112870362A (zh) * 2021-02-08 2021-06-01 中山大学附属第一医院 Circ-MET-1214和/或Circ-M50作为靶点在制备抗肿瘤药物中的用途
CN113234165A (zh) * 2021-05-07 2021-08-10 暨南大学 EpCAM的改造的结合蛋白及其应用
CN113402618A (zh) * 2021-06-30 2021-09-17 徐州医科大学 Ski在制备增效型CAR-T细胞中的应用
CN113512115A (zh) * 2021-08-09 2021-10-19 江苏省农业科学院 一种广谱识别小菜蛾中肠受体的抗Cry2Aa独特型单域抗体及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA149387A (en) 1913-05-22 1913-07-22 Andrew Jackson Coppock Means of priming explosive engines
CA151652A (en) 1913-08-23 1913-11-11 Per Erik Martin Norell Side bearing for cars
CA157738A (en) 1914-07-30 1914-09-08 John Martin Davis Aeroplane
DK100664C (da) 1960-05-11 1964-12-21 Friedrich Tonne Rørpostanlæg med automatisk styring af rørpostpatronernes bevægelse.
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
PL182237B1 (pl) 1994-03-07 2001-11-30 Dow Chemical Co Sposób przeprowadzania transfekcji komórek i osiagniecia biodostepnosci materialu genetycznego in vitro i ex vivo PL PL
WO1995034671A1 (en) 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US20020168342A1 (en) 1994-11-03 2002-11-14 Cell Genesys, Inc. Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5629184A (en) 1995-01-25 1997-05-13 Amgen Inc. Cationic copolymers of vinylamine and vinyl alcohol for the delivery of oligonucleotides
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
EP0844891A4 (en) 1995-08-11 2004-05-06 Dow Chemical Co HYPER COMBED POLYMER CONJUGATES
DE69824859T2 (de) 1997-04-14 2005-08-04 Cell Genesys, Inc., Foster City Methoden zur erhöhung der effizienz rekombinanter aav produkte
US5948878A (en) 1997-04-15 1999-09-07 Burgess; Stephen W. Cationic polymers for nucleic acid transfection and bioactive agent delivery
AU1819499A (en) 1997-12-12 1999-06-28 Samyang Corporation Positively-charged poly{alpha-(omega-aminoalkyl)glycolic acid} for the delivery of a bioactive agent via tissue and cellular uptake
AR018528A1 (es) 1997-12-12 2001-11-28 Expression Genetics Inc Mezcla polimerica biodegradable de micelas para transferencia genetica
US6169078B1 (en) 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
IL139761A0 (en) 1998-05-20 2002-02-10 Expression Genetics Inc A hepatocyte targeting polyethylene glyco-grafted poly-l-lysine polymeric gene carrier
WO2010037042A2 (en) * 2008-09-26 2010-04-01 The General Hospital Corporation Methods for detecting and treating cancer
US20130017199A1 (en) * 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
SG11201606577YA (en) * 2014-02-10 2016-09-29 Merck Patent Gmbh TARGETED TGFβ INHIBITION

Patent Citations (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083750A2 (en) * 2000-04-28 2001-11-08 The Johns Hopkins University Dendritic cell co-stimulator molecules
US20060110383A1 (en) * 2002-07-03 2006-05-25 Tasuku Honjo Immunopotentiative composition
US20050009149A1 (en) * 2002-10-11 2005-01-13 West James W. Production of homotrimeric fusion proteins
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
US8512701B2 (en) * 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
CN101124328A (zh) * 2004-12-15 2008-02-13 北卡罗来纳查佩尔山大学 嵌合载体
WO2007024715A2 (en) * 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
JP2015057442A (ja) * 2007-07-10 2015-03-26 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ Ｔｎｆスーパーファミリーコレクチン融合タンパク質
CN102282168A (zh) * 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
CN102250254A (zh) * 2010-05-19 2011-11-23 江苏先声药物研究有限公司 肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
CN103619351A (zh) * 2010-12-14 2014-03-05 詹姆斯·W·利拉德 用于预防和治疗癌症和癌细胞迁移的抗ccl25抗体和抗ccr9抗体
US20140086835A1 (en) * 2011-05-23 2014-03-27 The University Of North Carolina At Chapel Hill Methods and Compositions for Heptameric Targeting Ligands
CN103857699A (zh) * 2011-05-24 2014-06-11 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
CN104023711A (zh) * 2011-10-14 2014-09-03 Stc.Unm公司 用于靶向递送(包括负载物的透皮递送)的多孔纳米颗粒支撑的脂质双层(原始细胞)及其方法
WO2013071068A2 (en) * 2011-11-09 2013-05-16 Bristol-Myers Squibb Company Treatment of hematologic malignancies with an anti-cxcr4 antibody
CN104066449A (zh) * 2012-01-18 2014-09-24 霍夫曼-拉罗奇有限公司 抗lrp5抗体及使用方法
WO2014121085A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Pd-l1 and pd-l2-based fusion proteins and uses thereof
WO2015019284A2 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
CN105658237A (zh) * 2013-10-21 2016-06-08 基因泰克公司 抗Ly6E抗体及使用方法
US20150203579A1 (en) * 2014-01-23 2015-07-23 Regeneron Pharmaceuticals, Inc. Human Antibodies to PD-1
CN105085677A (zh) * 2014-05-05 2015-11-25 中国科学院上海药物研究所 抗vegfr2人源纳米抗体ntv1及其制备方法和用途
US20170218091A1 (en) * 2014-07-03 2017-08-03 Abbvie Inc. Monovalent binding proteins
CN107108707A (zh) * 2014-08-08 2017-08-29 小利兰斯坦福大学理事会 高亲和力pd‑1药剂以及使用方法
US20190381184A1 (en) * 2015-09-24 2019-12-19 The University Of North Carolina At Chapel Hill Methods and Compositions for Reducing Metastases
WO2017053170A1 (en) * 2015-09-24 2017-03-30 The University Of North Carolina At Chapel Hill Methods and compositions for reducing metastases
CN108079301A (zh) * 2016-11-23 2018-05-29 四川大学 减少cxcl13蛋白活性或表达量的活性物质在制备治疗恶性肿瘤转移药物中的用途
WO2018160572A1 (en) * 2017-02-28 2018-09-07 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising gitr-binding agents
CN112543643A (zh) * 2018-03-05 2021-03-23 肿瘤免疫股份有限公司 使用可溶性cd24用于治疗获得性免疫缺陷综合征（hiv/aids）的方法
CN110357960A (zh) * 2018-04-10 2019-10-22 广州爱思迈生物医药科技有限公司 抗体及抗体改造方法
CN112870362A (zh) * 2021-02-08 2021-06-01 中山大学附属第一医院 Circ-MET-1214和/或Circ-M50作为靶点在制备抗肿瘤药物中的用途
CN113234165A (zh) * 2021-05-07 2021-08-10 暨南大学 EpCAM的改造的结合蛋白及其应用
CN113402618A (zh) * 2021-06-30 2021-09-17 徐州医科大学 Ski在制备增效型CAR-T细胞中的应用
CN113512115A (zh) * 2021-08-09 2021-10-19 江苏省农业科学院 一种广谱识别小菜蛾中肠受体的抗Cry2Aa独特型单域抗体及其应用

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CHEN,T.: "aEP4G2, partial [Homo sapiens]", 《GENBANK DATABASE》 *
CHRISTINE FEIG等: "Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer", 《PNAS》 *
CUILING ZHONG等: "Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12", 《CLINICAL CANCER RESEARCH》 *
DAVID A. HARRIS等: "Inhibiting CXCL12 Blocks Fibrocyte Migration and Differentiation and Attenuates Bronchiolitis Obliterans in a Murine Heterotopic Tracheal Transplant Model", 《THE JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY》 *
ENAYETUL ISLAM: "Development of chemokine CXCL12-dependent immunotoxin against small cell lung cancer using in silico approaches", 《INFORMATICS IN MEDICINE UNLOCKED》 *
GELOVA,Z.等: "anti-cytokinin single chain Fv antibody [synthetic construct]", 《GENBANK DATABASE》 *
NCBI: "Chain A, Programmed Cell Death 1 Ligand 1", 《GENBANK DATABASE》 *
NCBI: "Chain A, Programmed Cell Death Protein 1", 《GENBANK DATABASE》 *
朱姜: "核糖体展示ScFv文库的构建及使用核糖体展示技术筛选壬基酚抗体", 《万方学位数据库》 *
李俊萱等: "CXCL12 及其受体与肿瘤生物学关系研究", 《中华中医药学刊》 *
王如东等: "肿瘤微环境响应脂质体阻断CXCL12/CXCR4 通路协同增加抗PD-1的免疫疗效", 《药学学报》 *
薛潇春: "PD--L1在角质形成细胞中的功能、调控及靛玉红干预研究", 《万方学位论文数据库》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109923123A (zh) * 2016-10-14 2019-06-21 爱默蕾大学 具有结合或阻断pd-l1的分子的纳米颗粒及其在治疗癌症中的用途
CN109923123B (zh) * 2016-10-14 2024-01-23 爱默蕾大学 具有结合或阻断pd-l1的分子的纳米颗粒及其在治疗癌症中的用途
CN113912695A (zh) * 2019-07-24 2022-01-11 暨南大学 靶向cd133的结合蛋白及应用
CN113912695B (zh) * 2019-07-24 2023-05-30 暨南大学 靶向cd133的结合蛋白及应用
WO2021043337A1 (zh) * 2019-09-06 2021-03-11 中国药科大学 一种多肽及其应用
CN115068496A (zh) * 2022-06-29 2022-09-20 四川大学 Dna四面体框架核酸和香蒲新苷的复合物及其制备治疗急性肾损伤的药物的用途
CN115068496B (zh) * 2022-06-29 2023-07-07 四川大学 Dna四面体框架核酸和香蒲新苷的复合物及其制备治疗急性肾损伤的药物的用途
CN118256447A (zh) * 2024-04-26 2024-06-28 中国医学科学院北京协和医院 一种高转移能力的胰腺癌类器官及其构建方法和应用

Also Published As

Publication number Publication date
US20190381184A1 (en) 2019-12-19
IL258292A (en) 2018-05-31
US11219694B2 (en) 2022-01-11
EP3352800A4 (en) 2019-03-27
WO2017053170A1 (en) 2017-03-30
ES2907486T3 (es) 2022-04-25
JP2018534255A (ja) 2018-11-22
CA2999756A1 (en) 2017-03-30
JP6933379B2 (ja) 2021-09-08
JP2021105060A (ja) 2021-07-26
EP3352800B1 (en) 2022-01-05
AU2016328279A1 (en) 2018-05-10
EP3352800A1 (en) 2018-08-01
KR20180063885A (ko) 2018-06-12
US20220168439A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
US20220168439A1 (en) Methods and compositions for reducing metastases
Erel-Akbaba et al. Radiation-induced targeted nanoparticle-based gene delivery for brain tumor therapy
US11498973B2 (en) BCMA-targeted chimeric antigen receptor as well as preparation method therefor and application thereof
AU2019262059B2 (en) Nanoparticles for gene expression and uses thereof
JP6145595B2 (ja) バイオ医薬の送達のためのエキソソーム
Goodwin et al. Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival
Li et al. Messenger RNA-based therapeutics and vaccines: what’s beyond COVID-19?
JP2019104738A (ja) 細胞内在化を誘導するためのｃｄ２０結合免疫毒素及びそれを用いる方法
CN105392888A (zh) 使用人源化抗cd19嵌合抗原受体治疗癌症
JP2021513355A (ja) 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用
CA3162629A1 (en) Nanoparticle systems to stimulate and maintain immune system responsiveness at treatment sites
WO2023016524A1 (zh) 联合her2和meso双靶点car-t载体及其构建方法和在癌症中的应用
US9683042B2 (en) T-cell-specific humanized single fragment antibody delivery vehicle
CN116284419A (zh) 靶向人gucy2c蛋白的单克隆抗体及其应用
CN111849905B (zh) 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法
JP2024534159A (ja) 導入遺伝子発現のための組成物および方法
KR20240017937A (ko) 치료제의 표적화된 전달을 위한 조성물 및 방법
JP2024535740A (ja) Ｃｄ３３を標的とする抗原認識受容体及びその使用
JP7590010B2 (ja) がん治療用医薬、免疫賦活剤および抗がん物質のスクリーニング方法
US20240409664A1 (en) Anti-pmepa-1 antibodies or antigen binding fragments thereof, compositions, and uses thereof
US20250235532A1 (en) Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof
Zhao et al. Senescence Reprogramming Unleashes Tumor Immune Surveillance via Coordinated Gene Modulation
CN118369332A (zh) 靶向cd33的抗原识别受体和其用途
WO2024220742A9 (en) Conjugated polyethyleneimine compounds and compositions, and uses thereof for the treatment of atherosclerosis, cardiovascular, and lung disease
WO2025101842A1 (en) Compositions and methods for targeted delivery of therapeutic agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180717

WD01 Invention patent application deemed withdrawn after publication